MedeliX
Start asking

bevacizumab

Avastin, Lytenava · ATC code L01FG01

Brand names: Avastin, Lytenava, Altuzan, Bevax, Mvasi, Zirabev

Key facts
Active substance
bevacizumab
ATC code
L01FG01
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Avastin 25 mg/ml concentrate for solution for infusion · Lytenava 25 mg/mL solution for injection
Marketing authorisation holder
Roche Registration GmbH, Outlook Therapeutics NL B. V.
Information as of
2026-10-27

Key facts

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF). As an infusion (Avastin) it is used in combination regimens for several metastatic cancers; as an intravitreal injection (Lytenava) for wet age-related macular degeneration.

What it is used for

  • Avastin: metastatic carcinoma of the colon or rectum with fluoropyrimidine-based chemotherapy (adults)
  • Avastin: first-line metastatic breast cancer with paclitaxel or capecitabine
  • Avastin: advanced non-small cell lung cancer other than predominantly squamous, with platinum-based chemotherapy, or with erlotinib for EGFR-activating mutations
  • Avastin: further indications (including gynaecological cancers) in the full text
  • Lytenava: neovascular (wet) age-related macular degeneration in adults

Dosing

  • Avastin, metastatic colorectal cancer: 5 mg/kg or 10 mg/kg every 2 weeks, or 7.5 mg/kg or 15 mg/kg every 3 weeks, as intravenous infusion
  • Avastin, metastatic breast cancer: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks
  • Avastin, NSCLC with platinum-based chemotherapy: 7.5 mg/kg or 15 mg/kg every 3 weeks for up to 6 cycles, then as a single agent
  • Avastin is continued until disease progression or unacceptable toxicity; further regimens in the full text
  • Lytenava: 1.25 mg by intravitreal injection every 4 weeks, monthly at first until maximum visual acuity, then individualised intervals

Contraindications

  • Hypersensitivity to the active substance or excipients
  • Avastin: hypersensitivity to CHO cell products or other recombinant human or humanised antibodies; pregnancy
  • Lytenava: active or suspected ocular or periocular infection; active intraocular inflammation

Important warnings

  • Avastin: increased risk of gastrointestinal perforation and fistulae; discontinue permanently if GI perforation occurs
  • Avastin: haemorrhage, including pulmonary haemorrhage/haemoptysis, more common in NSCLC
  • Avastin: arterial thromboembolism; hypertension and proteinuria are likely dose-dependent
  • Lytenava: endophthalmitis, intraocular inflammation and retinal detachment after intravitreal injection; monitor intraocular pressure after injection
  • Lytenava: not to be given with other systemic or ocular anti-VEGF medicines

Side effects

  • Avastin: most frequent are hypertension, fatigue or asthenia, diarrhoea and abdominal pain
  • Avastin: most serious are GI perforations, haemorrhage and arterial thromboembolism
  • Lytenava: most frequent are conjunctival haemorrhage, vitreous floaters, eye pain and increased intraocular pressure
  • Lytenava: less frequent but more serious: transient blindness, endophthalmitis, intraocular inflammation

Interactions

  • Avastin: no clinically relevant effect of co-administered chemotherapy on bevacizumab pharmacokinetics
  • Lytenava: no interaction studies; not to be combined with other anti-VEGF medicines

Pregnancy and breastfeeding

  • Avastin: contraindicated in pregnancy; women of childbearing potential use effective contraception during and up to 6 months after treatment
  • Lytenava: not used in pregnancy unless benefit outweighs risk; contraception during treatment and for at least three months after the last dose

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • Abevmy · biosimilarBiosimilar Collaborations Ireland Limited · EMEA/H/C/005327
  • Alymsys · biosimilarMabxience Research SL · EMEA/H/C/005286
  • AvastinRoche Registration GmbH · EMEA/H/C/000582
  • Avzivi · biosimilarFGK Representative Service GmbH · EMEA/H/C/005574
  • Aybintio · biosimilarSamsung Bioepis NL B.V. · EMEA/H/C/005106
  • LytenavaOutlook Therapeutics NL B. V. · EMEA/H/C/005723
  • Mvasi · biosimilarAmgen Europe B.V. · EMEA/H/C/004728
  • Oyavas · biosimilarSTADA Arzneimittel AG · EMEA/H/C/005556
  • Vegzelma · biosimilarCelltrion Healthcare Hungary Kft. · EMEA/H/C/005534
  • Zirabev · biosimilarPfizer Europe MA EEIG · EMEA/H/C/004697

Source: European Medicines Agency (EMA), product information

Turkey

  • AltuzanROCHE MÜSTAHZARLARI SAN.A.Ş. · 2 register entries
  • BevaxABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • MvasiAMGEN İLAÇ TİC. LTD. ŞTİ. · 2 register entries
  • ZirabevPFİZER PFE İLAÇLARI A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Abevmy, Alymsys, Avastin, Avzivi, Mvasi, Oyavas, Vegzelma, Zirabev
Liechtenstein
Abevmy, Alymsys, Avastin, Avzivi, Oyavas, Vegzelma, Zirabev
Norway
Abevmy, Alymsys, Avastin, Avzivi, Mvasi, Oyavas, Vegzelma, Zirabev

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Avastin – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf
  2. European Medicines Agency. Lytenava – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/lytenava-epar-product-information_en.pdf
  3. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.